SCHEMBL2572248

SCHEMBL2572248

NNC(=O)[C@H]1CC[C@H](c2cc(Cl)ccn2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.44
HDAC4 P56524 3/20 0.42
HDAC3 O15379 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
PROKR1 Q8TCW9 1/20 0.41
ACVRL1 P37023 2/20 0.40
KMT2A Q03164 1/20 0.40
TYK2 P29597 4/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BRAF P15056 1/20 0.39
JAK2 O60674 3/20 0.39
MAPT P10636 1/20 0.39
JAK1 P23458 1/20 0.39
CDK9 P50750 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2562591 1.00 GSK3B (0.44) GSK3BHDAC4HDAC3HDAC7HDAC8
SCHEMBL12262743 0.83 HDAC4 (0.42) GSK3BHDAC4HDAC3HDAC7HDAC8
SCHEMBL12238777 0.82 PDE4D (0.52) GSK3BHDAC4HDAC3HDAC7HDAC8
SCHEMBL2567056 0.82 PDE4D (0.52) GSK3BHDAC4HDAC3HDAC7HDAC8
SCHEMBL1937838 0.80 PROKR1 (0.43) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL2549348 0.78 RAB9A (0.46) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL2549343 0.78 RAB9A (0.46) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL2542233 0.75 MAPT (0.43) GSK3BHDAC3KMT2ASMN1; SMN2MAPT
SCHEMBL2542236 0.75 MAPT (0.43) GSK3BHDAC3KMT2ASMN1; SMN2MAPT
Cyanide SCHEMBL27987841 0.75 PROKR1 (0.41) HDAC4HDAC3HDAC7HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560975-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2013-02-27 EP disclosed
WO-2011131596-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-10-27 WO disclosed
US-20110263578-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES HOFFMANN-LA ROCHE, INC. 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263578-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AVPR1A, AVPR1B, OXTR GSK3B 3410/4885HDAC4 4481/4885HDAC3 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.